ORIGINAL CLINICAL EXPERIENCE AND APPROACH TO
TREATMENT STUDY WITH INTERLEUKINE 12/23 INHIBITOR IN
MODERATE-TO-SEVERE PSORIASIS PATIENTS
RODICA OLTEANU1, MARIA-MAGDALENA CONSTANTIN1,2*, ALEXANDRA ZOTA1, DANMIHAI DOROBANȚU1, TRAIAN CONSTANTIN2, ELENA-DANIELA ȘERBAN1, PAUL BĂLĂNESCU1, DANA MIHELE2, LAURA GHEUCĂ SOLOVĂSTRU3
1Colentina Clinical Hospital, Bucharest, Romania
2“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3“Gr. T. Popa” University of Medicine and Pharmacy, Iasi, Romania
*corresponding author: drmagdadinu@yahoo.com
Download Full Article

Abstract:
In recent years, there has been an increasing interest in developing new biologic treatments for psoriasis. Ustekinumab, an
interleukin (IL) IL12/IL23 inhibitor, has demonstrated real efficacy in treatment of psoriasis and psoriatic arthritis. We aimed
to describe our centre’s experience with this therapy. We included 15 patients (mean age 50.6 years and 2:1 male/female
ratio) with moderate-to-severe psoriasis, followed for 12 months. Over the course of the study, the patients received
ustekinumab as per usual protocol. Psoriasis area and severity index (PASI) and dermatological life quality index (DLQI)
scores were measured at 1, 3, 6, 9 and 12 months, PASI75 being the primary endpoint. A significant improvement in both
PASI and DLQI scores was seen in the first 16 weeks, with a plateau up until week 52. All patients achieved PASI75 and
93.3% PASI90 by month 12. Our experience with ustekinumab in the treatment of moderate-to-severe psoriasis showed
excellent results, with all patients reaching the primary endpoint of PASI75 by month 12. Further studies are needed to
determine long term efficacy and safety.

Top